Court Reverses: Paying Competing Drug Companies Not To Compete Is An Antitrust Violation

from the good-for-them dept

A few years ago, we wrote about a ridiculous situation in which big pharmaceutical companies were keeping prices artificially high by paying other drug companies to delay entering the market with generic drugs. The really scary part about this was that the big pharma companies would abuse patent law to force smaller drug companies into these deals. They’d file a patent infringement lawsuit, where they knew they had no leg to stand on, but the infringement filing forces the smaller generic maker into negotiations, where they often agree to a “license” which includes the delay — but the money flows in the opposite direction of a typical license. In other words, the whole lawsuit and the license is basically a sham to try to hide the agreement to prevent competition in the market. And, of course, as you probably know, when there’s no generic competition, drug makers are able to charge absurdly high prices for their drugs. As soon as there’s competition, the price often falls by more than 90%. Thus, the big drug companies have plenty of incentive to buy off the competition like this.

Many people have believed that such deals are clear antitrust violations — and a lawsuit against big pharma Schering-Plough (owned by Merck) tested this theory, only to be dismissed by the district court. That original ruling really twisted logic in a few knots to come to its conclusion — and the good news is that, two years later, the 3rd Circuit appeals court has reversed the ruling. The ruling is long, but interesting. It starts out by noting that other court’s ruling on this matter seem to take the concept of “patent validity” way too far. As we’ve discussed in other contexts, patent validity says that you have to assume a patent is valid — but in these cases, the court notes that this unfairly biases the situation in which the bogus patent infringement lawsuits are filed to extract these “pay-for-delay” deals.


First, we take issue with the scope of the patent test’s
almost unrebuttable presumption of patent validity. This
presumption assumes away the question being litigated in the
underlying patent suit, enforcing a presumption that the patent
holder would have prevailed. We can identify no significant
support for such a policy. While persons challenging the
validity of a patent in litigation bear the burden of defeating a
presumption of validity, this presumption is intended merely
as a procedural device and is not a substantive right of the
patent holder…. Moreover, the effectively conclusive presumption
that a patent holder is entitled to exclude competitors is
particularly misguided with respect to agreements – like those
here – where the underlying suit concerned patent
infringement rather than patent validity: In infringement cases
it is the patent holder who bears the burden of showing
infringement.

The court then discusses the Hatch-Waxman Act, which is at the heart of these disputes, noting that its intent (to increase availability of generics) seems to be the exact opposite of what happens with these pay-for-delay deals. But where it gets interesting is that the court says that having one company pay another to delay market entrance should be seen “as prima facie evidence of an unreasonable restraint of trade.” This is definitely a big ruling — though its potential disagreement with other courts may get this issue over to the Supreme Court before too long.

It’s nice to see the court get it right after the lower court seemed so confused by the issue.



Filed Under: , , , , , ,
Companies: merck, schering-plough

Rate this comment as insightful
Rate this comment as funny
You have rated this comment as insightful
You have rated this comment as funny
Flag this comment as abusive/trolling/spam
You have flagged this comment
The first word has already been claimed
The last word has already been claimed
Insightful Lightbulb icon Funny Laughing icon Abusive/trolling/spam Flag icon Insightful badge Lightbulb icon Funny badge Laughing icon Comments icon

Comments on “Court Reverses: Paying Competing Drug Companies Not To Compete Is An Antitrust Violation”

Subscribe: RSS Leave a comment
14 Comments
Vic Kleysays:

Re: "viral product"

I see so if I Mendocino Brewing Co., create by some means a new yeast that makes an unusually tasty beer my yeast is not a “product”?

Indeed it is a product and it does not matter how I honestly obtained it.

Note the word “honestly”. Honesty, integrity and ethics is utterly missing in the business practices of many fields and all civil litigation.

The justice system is broken and it will take a serious effort to make it right.

Most of the powers, and monied interests don’t want justice they prefer the tyranny of money. They are the tyrannts for they have the money.

FM hiltonsays:

Just the start of a reversal in fortunes

This is good news for those drug stores that have recently sued Teva and Wyeth Pharmaceuticals to delay the release of the generic version of Effexor: http://www.matkowsky.com/cvs-rite-aid-and-others-sue-wyeth-and-teva-pharmaceuticals-in-new-jersey-district-court/

When even the drug stores are suing the manufacturers of the products they sell, there’s a problem in the industry-one that can’t be ignored any longer.

It should have been patently (pun intended) obvious to all that this kind of kickback scheme is fraudulent in all aspects.

Good that the court finally realized the error of its’ ways, and reversed the original ruling.

Maybe someday the entire practice will be ruled illegal and heavy fines imposed retroactively on all the manufacturers. They’ve gotten away with too much to not be punished.

Prisoner 201says:

Re: They didn't get it right on purpose.

“It’s an election year. That means the funds that big pharma would normally spend to pay off judges has been diverted to presidential campaign funds. Lacking proper payment, good judgement kicked in.”

A more cynical take on it:

It’s a nice setup you have here, delaying generics. I haven’t seen any payments lately. It would be a shame if something were to happen to your little scheme…

Wallysays:

Good

Well that decision should be good news for my brother. He just turned 26 and recently got his own Health insurance plan through Ohio’s Medicade program. He ended up paying a $250 deductible plus another $150 for a 30 day supply of Concerta.

Now honestly, each person may find different formulas work better for them. Unlike the grocery market, generic products cary different properties for each generic forms. Just to site an example, Prozac (anti-depressant) comes in several forms:

1. Fluoxetine: Used to treat anxiety
2. Sarafem: OCD
3. Fontex: Earing disorders

Needless to say, this ruling opens a wide door towards better medication treatment over a wide variety of patients. Because each person reacts differently to different medications (some are better suited for generic) we will now have the ability to narrow down what the patient needs.

Vic Kleysays:

One topic where Masnick and I agree

Any actually enforced justice which returns balance to the public from the avarice of Big Pharma is great news.

Antitrust is actually a federal crime – a felony. Any deaths associated with such criminal?activity i.e. people who died because they could not afford their meds due to the antitrust induced pricing are manslaughters and every person and executive involved needs to spend some time in federal prison for every such occurrence. Big Pharma kills people through anti-trust crimes.

staffsays:

another biased article

“First, we take issue with the scope of the patent test?s almost unrebuttable presumption of patent validity…”

But then, you take issue with anything that keeps large infringers from stealing at will.

Masnick and his monkeys have an unreported conflict of interest-
https://www.insightcommunity.com/cases.php?n=10&pg=1

They sell blog filler and “insights” to major corporations including MS, HP, IBM etc. who just happen to be some of the world?s most frequent patent suit defendants. Obviously, he has failed to report his conflicts as any reputable reporter would. But then Masnick and his monkeys are not reporters. They are patent system saboteurs receiving funding from huge corporate infringers. They cannot be trusted and have no credibility. All they know about patents is they don?t have any.

Add Your Comment

Your email address will not be published. Required fields are marked *

Have a Techdirt Account? Sign in now. Want one? Register here

Comment Options:

Make this the or (get credits or sign in to see balance) what's this?

What's this?

Techdirt community members with Techdirt Credits can spotlight a comment as either the "First Word" or "Last Word" on a particular comment thread. Credits can be purchased at the Techdirt Insider Shop »

Follow Techdirt

Techdirt Daily Newsletter

Techdirt Insider Discord
The latest chatter on the Techdirt Insider Discord channel...
Loading...
Older Stuff
13:40 It's Great That Winnie The Pooh Is In The Public Domain; But He Should Have Been Free In 1982 (Or Earlier) (35)
12:06 Norton 360 Now Comes With Crypto Mining Capabilities And Sketchy Removal Process (28)
10:45 Chinese Government Dragnet Now Folding In American Social Media Platforms To Silence Dissent (14)
10:40 Daily Deal: The 2022 Ultimate Cybersecurity Analyst Preparation Bundle (0)
09:29 A Fight Between Facebook And The British Medical Journal Highlights The Difficulty Of Moderating 'Medical Misinformation' (9)
06:29 Court Ruling Paves The Way For Better, More Reliable Wi-Fi (4)
20:12 Eighth Circuit (Again) Says There's Nothing Wrong With Detaining Innocent Minors At Gunpoint (15)
15:48 China's Regulatory War On Its Gaming Industry Racks Up 14k Casualties (10)
13:31 Chinese Government Fines Local Car Dealerships For Surveilling While Not Being The Government (5)
12:08 Eric Clapton Pretends To Regret The Decision To Sue Random German Woman Who Listed A Bootleg Of One Of His CDs On Ebay (29)
10:44 ICE Is So Toxic That The DHS's Investigative Wing Is Asking To Be Completely Separated From It (29)
10:39 Daily Deal: The 2022 Complete Raspberry Pi And Arduino Developer Bundle (0)
09:31 Google Blocked An Article About Police From The Intercept... Because The Title Included A Phrase That Was Also A Movie Title (24)
06:22 Wireless Carriers Balk At FAA Demand For 5G Deployment Delays Amid Shaky Safety Concerns (16)
19:53 Tenth Circuit Denies Qualified Immunity To Social Worker Who Fabricated A Mother's Confession Of Child Abuse (35)
15:39 Sci-Hub's Creator Thinks Academic Publishers, Not Her Site, Are The Real Threat To Science, And Says: 'Any Law Against Knowledge Is Fundamentally Unjust' (34)
13:32 Federal Court Tells Proud Boys Defendants That Raiding The Capitol Building Isn't Covered By The First Amendment (25)
12:14 US Courts Realizing They Have A Judge Alan Albright Sized Problem In Waco (17)
10:44 Boston Police Department Used Forfeiture Funds To Hide Purchase Of Surveillance Tech From City Reps (16)
10:39 Daily Deal: The Ultimate Microsoft Excel Training Bundle (0)
09:20 NY Senator Proposes Ridiculously Unconstitutional Social Media Law That Is The Mirror Opposite Of Equally Unconstitutional Laws In Florida & Texas (25)
06:12 Telecom Monopolies Are Exploiting Crappy U.S. Broadband Maps To Block Community Broadband Grant Requests (7)
12:00 Funniest/Most Insightful Comments Of 2021 At Techdirt (17)
10:00 Gaming Like It's 1926: Join The Fourth Annual Public Domain Game Jam (6)
09:00 New Year's Message: The Arc Of The Moral Universe Is A Twisty Path (33)
19:39 DHS, ICE Begin Body Camera Pilot Program With Surprisingly Good Policies In Place (7)
15:29 Remembering Techdirt Contributors Sherwin And Elliot (1)
13:32 DC Metro PD's Powerful Review Panel Keeps Giving Bad Cops Their Jobs Back (6)
12:11 Missouri Governor Still Expects Journalists To Be Prosecuted For Showing How His Admin Leaked Teacher Social Security Numbers (39)
10:48 Oversight Board Overturning Instagram Takedown Of Ayahuasca Post Demonstrates The Impossibility Of Content Moderation (10)
More arrow
This site, like most other sites on the web, uses cookies. For more information, see our privacy policy. Got it